PT1503746E - Utilização farmacêutica de inibidores da cox-2 em perturbações oculares mediadas pela angiogénese - Google Patents

Utilização farmacêutica de inibidores da cox-2 em perturbações oculares mediadas pela angiogénese Download PDF

Info

Publication number
PT1503746E
PT1503746E PT03731699T PT03731699T PT1503746E PT 1503746 E PT1503746 E PT 1503746E PT 03731699 T PT03731699 T PT 03731699T PT 03731699 T PT03731699 T PT 03731699T PT 1503746 E PT1503746 E PT 1503746E
Authority
PT
Portugal
Prior art keywords
cox
angiogenesis
inhibitors
pharmaceutical use
ocular disorders
Prior art date
Application number
PT03731699T
Other languages
English (en)
Inventor
Romulus Kimbro Brazzell
George N Lambrou
Elisabeth Latour
Anna Ottlecz
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Publication of PT1503746E publication Critical patent/PT1503746E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT03731699T 2002-01-23 2003-01-22 Utilização farmacêutica de inibidores da cox-2 em perturbações oculares mediadas pela angiogénese PT1503746E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201520.4A GB0201520D0 (en) 2002-01-23 2002-01-23 Pharmaceutical uses

Publications (1)

Publication Number Publication Date
PT1503746E true PT1503746E (pt) 2008-01-10

Family

ID=9929598

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03731699T PT1503746E (pt) 2002-01-23 2003-01-22 Utilização farmacêutica de inibidores da cox-2 em perturbações oculares mediadas pela angiogénese

Country Status (17)

Country Link
US (3) US20050043410A1 (pt)
EP (1) EP1503746B1 (pt)
JP (1) JP2005515241A (pt)
CN (1) CN1283240C (pt)
AR (1) AR038198A1 (pt)
AT (1) ATE375154T1 (pt)
BR (1) BR0307013A (pt)
CA (1) CA2468811C (pt)
CY (1) CY1106994T1 (pt)
DE (1) DE60316792T2 (pt)
DK (1) DK1503746T3 (pt)
ES (1) ES2291641T3 (pt)
GB (1) GB0201520D0 (pt)
MY (1) MY145266A (pt)
PT (1) PT1503746E (pt)
TW (1) TWI280878B (pt)
WO (1) WO2003061645A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2005049014A1 (en) * 2003-11-18 2005-06-02 Pharmacia Corporation Cox-2 inhibitors for the treatment or prevention of diabetes-related ocular disorders
CN104306967A (zh) * 2008-09-10 2015-01-28 霍夫曼-拉罗奇有限公司 抑制眼部血管生成的方法
EP2429402A4 (en) * 2009-05-15 2017-03-15 Glaxosmithkline LLC Using thermal imaging for control of a manufacturing process
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652762A (en) * 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
CN1679556A (zh) * 1999-12-08 2005-10-12 法马西亚公司 维得克西组合物
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition
MXPA04006608A (es) * 2002-01-07 2004-10-04 Pharmacia Corp Tratamiento de dolor, inflamacion y trastornos relacionados con inflamacion con una combinacion de inhibidor selectivo de ciclooxigenasa-2 y aspirina.

Also Published As

Publication number Publication date
CY1106994T1 (el) 2012-09-26
CN1283240C (zh) 2006-11-08
DE60316792D1 (de) 2007-11-22
JP2005515241A (ja) 2005-05-26
WO2003061645A1 (en) 2003-07-31
TW200302081A (en) 2003-08-01
ES2291641T3 (es) 2008-03-01
CA2468811C (en) 2011-08-09
GB0201520D0 (en) 2002-03-13
CA2468811A1 (en) 2003-07-31
DK1503746T3 (da) 2008-02-04
AR038198A1 (es) 2005-01-05
CN1620288A (zh) 2005-05-25
DE60316792T2 (de) 2008-07-24
US20120322874A1 (en) 2012-12-20
ATE375154T1 (de) 2007-10-15
US20090247638A1 (en) 2009-10-01
US20050043410A1 (en) 2005-02-24
EP1503746B1 (en) 2007-10-10
MY145266A (en) 2012-01-13
TWI280878B (en) 2007-05-11
EP1503746A1 (en) 2005-02-09
BR0307013A (pt) 2004-11-03

Similar Documents

Publication Publication Date Title
TWI347844B (en) Sulfoximine-substituted pyrimidines as cdk-and/or vegf inhibitors, their production and use as pharmaceutical agents
HK1208865A1 (en) Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors 6 pde4
EP1827391A4 (en) DOSAGE FORMS AND METHODS OF USE THEREOF
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
AU2003303128A8 (en) Inhibitors and methods of use thereof
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
HK1078779A1 (en) Substituted benzazoles and use thereof as raf kinase inhibitors
EP1465615A4 (en) TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE
ZA200501381B (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL165395A0 (en) Use of thio-oxubdile derivatives in treatment of hormone-related conditions
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
AU2003290939A8 (en) Replication of biological tiussue
PT1503746E (pt) Utilização farmacêutica de inibidores da cox-2 em perturbações oculares mediadas pela angiogénese
SI1503746T1 (sl) Farmacevtska uporaba cox-2 inhibitorjev v ocesnihboleznih povezanih z angiogenezo
AU2003236843A1 (en) Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2003294697A8 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
ZA200704412B (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
AU2002339689A1 (en) Dexar agonists and antagonists for use in the treatment of metabolic disorders
AU2002328172A1 (en) Agonists and antagonists of modumet for use in the treatment of metabolic disorders
AU2002339674A1 (en) Ditacin agonists and antagonists for use in the treatment of metabolic disorders